The results show that, in HCC cell lines, co-treatment with HDACi (apicidin 10 μM and SAHA 3 μM) and fisetin (10–90 μM) significantly reduced cell viability in a dose-dependent manner compared with the HDAC inhibitors alone (Figure 2A,B). Here, HDAC9 is linked to hepatocellular carcinoma.